OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111) [clinicaltrials:NCT00076089]

Bio2RDF uri

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111) [clinicaltrials:NCT00076089]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00076089

Bio2RDF identifier

NCT00076089

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00076089

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00076089

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ive pulmonary disease (COPD).

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

OPUS Study: Effect of Roflumil ...... lmonary Disease (BY217/M2-111)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

change in FEV1 from baseline during the treatment period; number of COPD exacerbations. [clinicaltrials_resource:b41d14678ee749b07b63b80f22b77b2f]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

change in FEV1 from baseline during the treatment period; number of COPD exacerbations. [clinicaltrials_resource:0497480b478cfdddb4db859ed67954dc]

change in FEV1 from baseline during the treatment period; number of COPD exacerbations. [clinicaltrials_resource:1fc597fee71353474667dca47bb82d0a]

change in FEV1 from baseline during the treatment period; number of COPD exacerbations. [clinicaltrials_resource:461d59c9f1f671589e304c46cbdc68cc]

change in FEV1 from baseline during the treatment period; number of COPD exacerbations. [clinicaltrials_resource:6c9748bbd71aec32183c17095de64c60]

change in FEV1 from baseline during the treatment period; number of COPD exacerbations. [clinicaltrials_resource:868a0ae8b3d4eb89ef33bf5e0903368c]

change in FEV1 from baseline during the treatment period; number of COPD exacerbations. [clinicaltrials_resource:ab6dee69b62ecdca1c8408e4fb54c566]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00076089 [clinicaltrials_resource:f4afb8f9b5a52b5980a06b27e50ff8d4]

enrollment [clinicaltrials_vocabulary:enrollment]

1.100

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2004-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Roflumilast [clinicaltrials_resource:e1572455e6782204e10d9f6b068efab4]

keyword [clinicaltrials_vocabulary:keyword]

COPD

http://www.w3.org/2001/XMLSchema#string

Chronic obstructive pulmonary disease

http://www.w3.org/2001/XMLSchema#string

Roflumilast

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Takeda [clinicaltrials_resource:be0157d7addd538bdf1562821c5e86fc]

location [clinicaltrials_vocabulary:location]

ALTANA Pharma [clinicaltrials_resource:7fd45f7350714d26eb54a858e05359b1]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00076089

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Effect of Roflumilast on Exace ...... ast Once Daily Versus Placebo.

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

BY217/M2-111

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Delbert Meyer, M.D. [clinicaltrials_resource:2daef087844a33b8716750b11d1f2c92]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Takeda [clinicaltrials_resource:be0157d7addd538bdf1562821c5e86fc]

start date [clinicaltrials_vocabulary:start-date]

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00076089 study design [clinicaltrials_resource:2203678ee44b995dd475f0aaca9ab7c9]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00076089

verification date [clinicaltrials_vocabulary:verification-date]

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00076089

http://www.w3.org/2001/XMLSchema#string

title

OPUS Study: Effect of Roflumil ...... lmonary Disease (BY217/M2-111)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

OPUS Study: Effect of Roflumil ...... ) [clinicaltrials:NCT00076089]

@en